3 ms·
Hey shiven! Thanks for your question. This is Ian Cinnamon from the Immunity Project team. The targets we are trying to immunize with are believed to be benef
by icinnamon 13y ago
Hey shiven! Thanks for your question. This is Ian Cinnamon from the Immunity Project team.
The targets we are trying to immunize with are believed to be beneficial by a statistical analysis similar to what is described here:
Mothe B, Anuska L, Ibarrondo J, Daniels M, Miranda C, Zamarreno J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine 2011;9(208):20.
The guys who generated the peptides we are using have specifically asked us not to talk about the sequences because they are trying to publish now. We hope that these targets will be conserved to the point that resistance is limited (as may be the case in some HIV controllers) - won't know without clinical data.
- shiven 13y agoThanks for answering with a reference! I am not asking about the peptide sequence, just the protein it is derived from. But, if you cannot share that right now, that's OK too. I'll look out for the publication. However, assuming I am making an educated guess about the parent protein, I'd go with gp120/gp41 envelope (env). I may be totally wrong there and you guys may have another ace up your sleeve (do hope so, fingers crossed!). Good luck!
- reidrubsamen 13y agoThanks very much for the kind note! I would be happy to send you a link to the paper the guys working on the statistical analysis of beneficial HIV target regions when it is published.
- jarrodk 13y agoHow can you possibly say that resistance may be limited without further clinical tests, but have a project literally stating you can cure HIV - and distribute it for free?